Storys zum Thema Economy

29.06.2005 – 10:02
World Federation for Mental Health
Global Survey Reveals Personal Impact of Bipolar Disorder
Vienna, Austria (ots/PRNewswire) - - World Federation for Mental Health urges better understanding, treatment and management to improve outcomes for people living with bipolar disorder The World Federation for Mental Health (WFMH) today announced results of a global bipolar disorder consumer survey, Thinking Ahead, at the World Congress of Biological Psychiatry. The survey revealed that almost half (47%) of ...
mehr
28.06.2005 – 12:44
ProMetic Life Sciences
Alliance Between MacoPharma, ProMetic and PRDT Leads to New Advances in Prion Removal Filter
LILLE, France and MONTREAL, Québec, June 28 (ots/PRNewswire) - The latest scientific data on MacoPharma's prion filter device will be presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) being held in Athens, Greece on July 4, 2005, MacoPharma and ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI.SV) announced ...
mehr
27.06.2005 – 07:32
Roche Pharmaceuticals
Tarceva Receives Positive Opinion in EU for the Treatment of Patients With Lung Cancer
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative, oral cancer medicine Tarceva (erlotinib) has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of non-small cell lung cancer, the most common form of lung cancer. "This decision is proof of the impressive ...
mehr
23.06.2005 – 13:53
Boehringer Ingelheim GmgH
U.S. FDA Approves New Anti-HIV Drug Aptivus(R) for Use in Combination Therapy
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
mehr
23.06.2005 – 13:03
Merge Healthcare
AZ Sint-Lucas Hospital Installs New FUSION PACS(TM) System Integrated Solution for Digital Imaging From Merge Healthcare
Milwaukee and Toronto (ots/PRNewswire) - Cedara, a Merge Healthcare company (Nasdaq: MRGE), and a leading independent developer of medical software technologies for the global healthcare market, and their Distributor in the Benelux, ImaXperts BV, have finalized the installation of a new FUSION PACS(TM) for the ...
mehr
23.06.2005 – 09:24
Zeltia S.A.
Zeltia Raises EUR 65 Million Through Institutional Placing
Madrid (ots/PRNewswire) - Zeltia S.A.(ZEL SM; ZEL.MC), the Spanish biotechnology company, today announces that it has raised Eur 65 million of new funds through a private placement of 10.75 million new ordinary shares with qualified institutional investors at a price of Eur 6.05 per share. This transaction is one of the four largest executed in European biotech in the last four years. The funds raised will be used ...
mehr

21.06.2005 – 19:12
Zeltia and PharmaMar
Zeltia to Raise New Funds Through Institutional Placing
Madrid, Spain (ots/PRNewswire) - Zeltia S.A, the Spanish consumer chemicals and biotechnology group announces today that its Board of Directors has authorized a capital increase through a private placement with qualified international institutional investors. The capital increase is expected to raise approximately one hundred (100) million euros. A "green shoe" of up to 15% of the amount raised can be exercised by ...
mehr
20.06.2005 – 14:17
Ferring International SA
New Study Adds Weight to Clinical Merit of MENOPUR in IVF
Copenhagen, Denmark (ots/PRNewswire) - - "Approximately five more pregnancies per 100 women treated" with MENOPUR compared to recombinant treatment New data presented today at the ESHRE (European Society of Human Reproduction and Embryology) congress supports the efficacy of MENOPUR (menotrophin), a highly purified, naturally-derived infertility treatment belonging to the class of drugs known as gonadotrophins, ...
mehr
17.06.2005 – 08:36
Roche Pharmaceuticals
Revolutionary Treatment Avastin Helps People with Advanced Colorectal Cancer Live Longer While Preserving Their Quality of Life
Barcelona, Spain (ots/PRNewswire) - The addition of Avastin(R) (bevacizumab, rhuMAb-VEGF) to chemotherapy increases the survival of patients with advanced colorectal cancer while also preserving their quality of life for longer according to new data presented today at the 7th World Congress on Gastrointestinal ...
mehr
15.06.2005 – 10:19
Orion Corporation
Orion Diagnostica to Transfer Production From Oulunsalo to Turku
Espoo, Finland (ots/PRNewswire) - Negotiations have been completed with the personnel representatives in Orion Diagnostica Oy, a subsidiary of Orion Corporation, concerning operational rearrangements at Orion Diagnostica's sites in Finland. As a result of the negotiations, a decision has been made to transfer the production operations of the Oulunsalo plant to Turku. There are 30 employees at the Oulunsalo site. ...
mehr
13.06.2005 – 15:12
sanofi-aventis Group
U.S. FDA Licenses Sanofi Pasteur's ADACEL(TM) Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis
Swiftwater, Pennsylvania and Lyon, France (ots/PRNewswire) - - First and Only Booster in the U.S. for Protection Against Pertussis from Adolescence through Adulthood Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration ...
mehr
13.06.2005 – 15:09
Cephalon
Cephalon, Inc. Announces Acquisition of TRISENOX(R) from Cell Therapeutics, Inc.
Frazer, Pennsylvania (ots/PRNewswire) - - Transaction Accelerates Cephalon's Entry into Oncology Market and Builds Platform for its Growing Oncology Franchise Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement with Cell Therapeutics, Inc. (Nasdaq and Nuovo Mercato: CTIC) and CTI Technologies, Inc., a wholly owned subsidiary of ...
mehr

13.06.2005 – 12:57
Cephalon
Cephalon, Inc. Announces Acquisition of TRISENOX(R) from Cell Therapeutics, Inc.
Frazer, Pennsylvania (ots/PRNewswire) - - Transaction Accelerates Cephalon's Entry into Oncology Market and Builds Platform for its Growing Oncology Franchise Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement with Cell Therapeutics, Inc. (Nasdaq and Nuovo Mercato: CTIC) and CTI Technologies, Inc., a wholly owned subsidiary of ...
mehr
10.06.2005 – 08:17
Abbott Laboratories
Abbott's HUMIRA(R) (Adalimumab) Shown to Improve Quality of Life for Psoriatic Arthritis Patients
Vienna, Austria (ots/PRNewswire) - - Data from ADEPT study showed HUMIRA slowed progression of structural joint damage Results from Abbott's Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) show that HUMIRA(R) (adalimumab) treated both joint and skin aspects of the disease and improved the quality of life measurements in patients with moderate ...
mehr
09.06.2005 – 17:08
Cordis Medizinische Apparate GmbH
Cordis Corporation to Appeal Court Ruling
Miami (ots/PRNewswire) - Cordis Corporation, a Johnson & Johnson company, today received a ruling from a court in the Netherlands that found the company infringed a Boston Scientific patent related to a catheter shaft that is used in the delivery system for the CYPHER(R) and CYPHER(R) Select Sirolimus-eluting Coronary Stents, as well as several other catheter-based products. Cordis intends to file an appeal with the ...
mehr
06.06.2005 – 18:31
Amgen Inc.
Final Results of a Phase 3 European Study Demonstrate Aranesp(R) Dosed Once Every Three Weeks is at Least as Effective as Weekly Dosing in Treating Patients With Chemotherapy-Induced Anaemia
Stockholm, Sweden (ots/PRNewswire) - Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, announced that new data from a randomised, double-blind Phase 3 study demonstrate that Aranesp(r) (darbepoetin alfa) administered as a fixed dose of 500 mcg once every three weeks is at least as effective as ...
mehr
02.06.2005 – 22:05
Quintiles Transnational Corp.
Quintiles Laboratories Asia Enhances Services in China
Research Triangle Park, North Carolina (ots/PRNewswire) - Quintiles Transnational Corp. today announced that Quintiles Laboratories Asia (QLAB Asia) has amended its existing agreement with Peking Union Medical College Hospital (PUMCH) to enhance central laboratory services in China. The new amended agreement with PUMCH enhances services for customers by allowing Quintiles central laboratory (QLAB) facilities in ...
mehr
02.06.2005 – 14:07
Cytochroma Inc.
Cytochroma Reports Successful Efficacy Trial for Novel Topical Treatment of Psoriasis
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis. The study, involving 17 healthy subjects with mild to moderate plaque psoriasis, was designed to characterize the local efficacy and safety of three concentrations of CTA018. Results ...
mehr

02.06.2005 – 08:39
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals Announces Exclusive Collaboration With Novartis to Develop and Commercialize ANA975 and Additional TLR7-Based Therapeutics for Hepatitis C and Hepatitis B
San Diego, California (ots/PRNewswire) - - Total Partnership Valued at Up to USD$570 Million in Upfront and Potential Milestone Payments Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has entered into an exclusive global license and co-development agreement with Novartis to develop, ...
mehr
24.05.2005 – 22:05
Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals Announces Acquisition of Worldwide Rights to Amphotec(R)/Amphocil(R)
Cranberry Township, Pennsylvania (ots/PRNewswire) - Three Rivers Pharmaceuticals, LLC announced today that it has completed the acquisition of worldwide ownership of Amphotec(R)/Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) from InterMune, Inc. (Nasdaq: ITMN). Amphotec is indicated for the treatment of invasive aspergillosis, a fungal ...
mehr
24.05.2005 – 17:26
BioWa, Inc.
BioWa and Medarex Announce Expansion of Licensing Agreement for BioWa's Potelligent(TM) Technology
Princeton, New Jersey (ots/PRNewswire) - - BioWa Grants the Second Potelligent(TM) Antibody Technology License to Medarex BioWa, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent(TM) Technology for the enhancement of ...
mehr
24.05.2005 – 13:11
Infotrieve, Inc.
Infotrieve Introduces the Life Science Research Center
Los Angeles (ots/PRNewswire) - Infotrieve, Inc. announced today the immediate availability of the company's Life Science Research Center(TM) (LSRC), a web-based information research tool that provides scientists with one-stop search access to critical information that impacts scientific workflow. The LSRC was designed to simplify research by eliminating the need for logins to multiple information sources including ...
mehr
18.05.2005 – 15:05
Eli Lilly and Company
Non-Stimulant Strattera More Widely Available for Attention-Deficit/Hyperactivity Disorder Patients in Europe
Indianapolis (ots/PRNewswire) - - Europe's only approved non-stimulant ADHD medication offers a new treatment choice Eli Lilly and Company's Strattera(R), the only approved non-stimulant medication proven clinically effective(1) at treating the potentially serious symptoms of ...
mehr
17.05.2005 – 14:26
IBCSG
Web Cast Announcing Promising News from ASCO for Early Breast Cancer Patients
Orlando, Florida (ots/PRNewswire) - - Landmark Study Big 1-98 Shows Letrozole Offers Greater Protection from Recurrence of Early Breast Cancer than Tamoxifen - Web Cast Briefing Available at 17 May 2005 8:00 AM EDT http://www.ibcsg.org/index.shtm Newly updated results of the independent Breast International Group 1-98 trial just released at ASCO show ...
mehr

16.05.2005 – 13:15
Eli Lilly and Company
European School of Oncology Announces Viktoria Kun and Ioanna Soufleri As Joint Winners of ACE Reporter Award 2005
Orlando, Florida (ots/PRNewswire) - Viktoria Kun, Health Correspondent on the Hungarian national daily newspaper Népszabadság, and Ioanna Soufleri, Science Editor on the Greek national daily newspaper To Vima, have been named today by The European School of Oncology (ESO) as joint winners of the ACE (Awarding ...
mehr
16.05.2005 – 08:40
PharmaMar and Zeltia Group
YONDELIS(TM) (trabectedin) Phase II Trials Demonstrate Activity in Prostate, Ovarian and Breast Cancer
Orlando, Florida (ots/PRNewswire) - - New Results Presented at ASCO Results from five clinical studies of YONDELIS (TM) (trabectedin) were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), in Orlando, Florida, from 13-17 May 2005. YONDELIS is being developed by PharmaMar ...
mehr
14.05.2005 – 21:01
Roche Pharmaceuticals
Tarceva(tm) Extends Life for Patients With Pancreatic Cancer
Basel, Switzerland (ots/PRNewswire) - The addition of Tarceva(tm) (erlotinib) to chemotherapy extends survival by 23.5% for patients with advanced pancreatic cancer, according to data presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, USA.(1) Tarceva, an advanced new cancer drug taken as a once-daily tablet, has already demonstrated a clear survival benefit for patients with ...
mehr
13.05.2005 – 23:02
Roche Pharmaceuticals
New Avastin(R) Study Shows Dramatic Survival Benefits for Patients With Metastatic Breast Cancer
Basel, Switzerland (ots/PRNewswire) - - Anti-Angiogenic Treatment Shows Survival Benefit Across Three Major Cancer Types: Breast, Lung And Colorectal Cancer A new study with Avastin(R) (bevacizumab, rhuMAb-VEGF) today reported that when used in combination with chemotherapy, Avastin doubled the chances of ...
mehr
13.05.2005 – 22:03
Roche Pharmaceuticals
Avastin(R) Demonstrates Impressive Survival Benefit in Lung Cancer Study
Basel, Switzerland (ots/PRNewswire) - - Addition of Avastin Boosts Efficacy of First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer A new study, presented for the first time today, reveals that Avastin(R) (bevacizumab rhuMAb-VEGF) significantly extends survival for patients with previously untreated, advanced non-small cell lung cancer (NSCLC), ...
mehr
13.05.2005 – 21:31
Sorin Group
Sorin Group: The Board of Directors Approves the Results for the First Quarter Of 2005: Results in Line With Expectations
Milan, Italy (ots/PRNewswire) - - Net Revenues Grow to 179.3 Million Euros in the First Quarter of 2005, or 1.8% More Than in the Same Period Last Year.(1) - EBITDA Total 16.5 Million Euros, Compared With 18.2 Million Euros in 2004, Improving 5.1% vs. Same Period Last Year (net of Exceptional Items of 2.5 ...
mehr

Vorherige73747576777879808182Nächste